Horizon Therapeutics PLC (HZNP) News
Filter HZNP News Items
HZNP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HZNP News Highlights
- For HZNP, its 30 day story count is now at 9.
- Over the past 23 days, the trend for HZNP's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ACT, RARE and ST are the most mentioned tickers in articles about HZNP.
Latest HZNP News From Around the Web
Below are the latest news stories about HORIZON THERAPEUTICS PUBLIC LTD CO that investors may wish to consider to help them evaluate HZNP as an investment opportunity.
Should You Invest in Horizon Therapeutics Public Limited Company (HZNP)?Renaissance Investment Management, an investment management company, released its “Midcap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy returned 11.23% (net) compared to a 6.90% return for the Russell Midcap Growth Index. The strategy declined -13.42% (net) in 2022 compared to a -26.72% decline […] |
Here's Why Horizon Therapeutics (HZNP) is a Strong Growth StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)DUBLIN, March 16, 2023--Horizon Therapeutics plc (NASDAQ: HZNP): |
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)DUBLIN, March 14, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being presented during the 49th annual meeting of the North American Neuro-Ophthalmology Society (NANOS) March 11-16, 2023, in Orlando, Florida. |
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)DUBLIN, March 12, 2023--Horizon Therapeutics announced new data on the use of TEPEZZA (teprotumumab-trbw) in patients with dysthyroid optic neuropathy (DON) at NANOS 2023. |
7 Over-$100 Stocks That Are Worth Every PennyTo get most of the best-known stocks, you have to be prepared to pay at least $100 per share. |
Horizon Therapeutics plc - Rule 2.12 AnnouncementDUBLIN, March 01, 2023--In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on February 23, 2023, Horizon’s issued ordinary share capital is comprised of 228,832,390 ordinary shares, nominal value $0.0001 per share (the "Ordinary Shares") and 40,000 deferred ordinary shares of €1.00 each. The Company has 384,366 Ordinary Shares which are held as treasury shares. The Ordinary Shar |
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial ResultsDUBLIN, March 01, 2023--Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results |
Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant ProgramDUBLIN, February 28, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that applications for its 2023 #RAREis Global Advocate Grant are open through March 31, 2023. To increase impact and support advocates who are catalysts for rare disease community needs, #RAREis will grant 50 groups with a one-time $5,000 grant. In 2022, the company awarded 30 grants to advocacy organizations. |
Horizon Therapeutics plc Announces Voting Results from Special Shareholder MeetingsDUBLIN, February 24, 2023--Horizon Therapeutics plc (NASDAQ: HZNP): |